CereVasc, Inc. Announces Publication of A Multi-Center Study Evaluating the eShunt® System in the Treatment of Patients with NPH

CereVasc, Inc., a clinical-stage medical device company developing novel treatments for neurological diseases, today ...

Study identifies long-term health risks in testicular cancer survivors treated with contemporary chemotherapy

A large, multi-center study published online in the Journal of the National Comprehensive Cancer Network (JNCCN) provides new insight into the long-term health effects of contemporary chemotherapy ...
ascopubs.org

ADAGIO: A Phase IIb, Open-Label, Single-Arm, Multicenter Study Assessing the Efficacy and Safety of Adavosertib (AZD1775) as Treatment for Recurrent or Persistent Uterine ...

Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA Mutation Eligible patients ...
Medical Dialogues

Multi-Modal AI Cuts Mammography Workload by 43.8% While Preserving 100% Sensitivity: Study Finds

Effective Patient Triaging: Prospective clinical data demonstrated a significant reduction in recall rates for low-risk cases, decreasing from 7.6% to 5.7%, which minimizes nonessential follow-up ...

Adagio Medical (ADGM) announces successful results from US cardiac ablation feasibility study

Adagio Medical Holdings Inc. (NASDAQ:ADGM) is one of the best up and coming penny stocks to buy. On February 4, Adagio Medical Holdings announced the publication of results from its US Early ...
ascopubs.org

Prospective Multicenter Study Evaluating a Combined Circulating Tumor DNA and Circulating Tumor RNA Liquid Biopsy in Metastatic Non–Small Cell Lung Cancer (LIQUIK)

This multicenter, prospective study (ClinicalTrials.gov identifier: NCT04703153) enrolled patients across the United States and Singapore. Patients were tested with tissue NGS, LHM, and G360 ctDNA.